A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
163 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
140 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
DETECT-ME
Recruiting
700 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
DUAL-NK-PDAC
Phase 1/2 Recruiting
42 enrolled
A Study of KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy as First-line Treatment in Patients With Advanced Esophageal Cancer
Phase 2 Recruiting
60 enrolled
A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in Participants With Pancreatic Cancer
Phase 1 Recruiting
12 enrolled
A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer
Phase 2 Recruiting
327 enrolled
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Phase 2 Recruiting
172 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 Recruiting
135 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
SERENTA
Phase 3 Recruiting
168 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
FRUITION
Phase 2 Recruiting
120 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 2/3 Recruiting
990 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Phase 1/2 Recruiting
252 enrolled
ORI-EGI-03
Recruiting
450 enrolled
MOUNTAINEER-03
Phase 3 Recruiting
400 enrolled
ARTIA-Pancreas
Phase NA Recruiting
134 enrolled
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Phase 1 Recruiting
710 enrolled
MK-3475-06D
Phase 1/2 Recruiting
210 enrolled
MK-3475-06C
Phase 1/2 Recruiting
160 enrolled
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
Phase 1/2 Recruiting
180 enrolled
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Phase 3 Recruiting
726 enrolled
A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
Phase 2 Recruiting
100 enrolled
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Phase 1 Recruiting
246 enrolled
FAPI-GO
Phase 3 Recruiting
200 enrolled
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Phase 3 Recruiting
700 enrolled
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Phase 2 Recruiting
88 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Phase 1/2 Recruiting
342 enrolled
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Phase 1/2 Recruiting
1,130 enrolled
DEL-LIVER
Phase 2 Recruiting
90 enrolled
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Phase 1 Recruiting
220 enrolled
Feasibility Study of CBCT for IGRT in Cancer Patients
Phase NA Recruiting
50 enrolled
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Phase 2 Recruiting
140 enrolled
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Phase 1 Recruiting
25 enrolled
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Phase 1 Recruiting
380 enrolled
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Phase 1 Recruiting
180 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled